CliffBio
small molecule

RESERPINE AND HYDROFLUMETHIAZIDE

HYDROFLUMETHIAZIDE; RESERPINE

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameRESERPINE AND HYDROFLUMETHIAZIDE
Active ingredientHYDROFLUMETHIAZIDE; RESERPINE
Strength50MG;0.125MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 1985
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.